Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4444864 | 1.00 | ATM (0.60) | ATMCYP3A4TSHRCA1CA2 | |
| SCHEMBL2851560 | 1.00 | ATM (0.60) | ATMCYP3A4TSHRCA1CA2 | |
| Hydrochloric Acid SCHEMBL2853606 | 0.99 | ATM (0.59) | ATMCYP3A4TSHRCA1CA2 | |
| Hydrochloric Acid SCHEMBL2853610 | 0.99 | ATM (0.59) | ATMCYP3A4TSHRCA1CA2 | |
| SCHEMBL21469067 | 0.90 | ATM (0.68) | ATMCYP3A4TSHRMEN1LMNA | |
| SCHEMBL8530402 | 0.90 | ATM (0.68) | ATMCYP3A4TSHRMEN1LMNA | |
| SCHEMBL30460502 | 0.90 | ATM (0.68) | ATMCYP3A4TSHRMEN1LMNA | |
| SCHEMBL21399728 | 0.89 | CYP3A4 (0.64) | ATMCYP3A4TSHRLMNAALDH1A1 | |
| SCHEMBL2853604 | 0.89 | ATM (0.57) | ATMCYP3A4TSHRCA1CA2 | |
| SCHEMBL6558237 | 0.89 | ATM (0.57) | ATMCYP3A4TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696665-B2 | Mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2019-09-26 | — | — | US | disclosed |
| EP-1378247-B1 | VISUAL FUNCTION DISORDER IMPROVING AGENTS | SENJU PHARMA CO (JP) | 2016-08-24 | — | — | EP | disclosed |
| CN-1867551-B | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | RAQUALIA PHARMA INC | 2013-09-11 | — | — | CN | disclosed |
| CN-101310771-B | Visual function disorder improving agents | SENJU PHARMA CO | 2012-08-08 | — | — | CN | disclosed |
| EP-1391454-B1 | Substituted benzamide compounds with antihypertensive activity | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7696194-B2 | treating with fasudil hydrochloride; enzyme inhibitor of Rho kinase; promoting regeneration of an optic nerve cell | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| CN-101310771-A | Visual function disorder improving agents | SENJU PHARMA CO (JP) | 2008-11-26 | — | — | CN | disclosed |
| CN-100411686-C | Agent for improving visual function disorder | SENJU PHARMA CO (JP) | 2008-08-20 | — | — | CN | disclosed |
| US-20070191420-A1 | Kinase inhibitors | DEVGEN NV | 2007-08-16 | — | — | US | disclosed |
| WO-2005082367-A1 | KINASE INHIBITORS | DEVGEN NV (BE) | 2005-09-09 | — | — | WO | disclosed |
| US-20040106646-A1 | Visual function disorder improving agents | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| CN-1501813-A | Agent for improving visual function disorder | 千寿制药株式会社 | 2004-06-02 | — | — | CN | disclosed |
| EP-1391454-A1 | Substituted benzamide compounds with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1378247-A1 | VISUAL FUNCTION IMPROVING AGENTS | Senju Pharmaceutical Co., Ltd. (JP) | 2004-01-07 | — | — | EP | disclosed |
| EP-0757038-B1 | BENZAMIDE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1195372-A1 | N-heterocyclic substituted benzamide derivatives with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2002-04-10 | — | — | EP | disclosed |
| US-6156766-A | Benzamide compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-5958944-A | TREATMENT OF CIRCULATORY DISEASES IN CORONARY, CEREBRAL, RENAL AND PERIPHERAL ARTERIES, AS A THERAPEUTIC AGENT FOR HYPERTENSION, ANGINA PECTORIS, AND RENAL AND PERIPHERAL CIRCULATION DISORDER, ANTIASTHMATIC AGENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| EP-0757038-A1 | BENZAMIDE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696665-B2 | Mutant IDH1 inhibitors | IDH1, IDH3B, IDH3A | ATM 286/4885CYP3A4 3737/4885TSHR 4122/4885 |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | IDH1, IDH3B, IDH3A | ATM 286/4885CYP3A4 3737/4885TSHR 4122/4885 |
| US-20040106646-A1 | Visual function disorder improving agents | ARHGDIA, GAP43, RHOT2 | ATM 3841/4885CYP3A4 4867/4885TSHR 3361/4885 |
| US-20070191420-A1 | Kinase inhibitors | ROCK1, ROCK2, MAP3K20 | ATM 617/4885CYP3A4 2766/4885TSHR 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.